09:52 AM EST - Theratechnologies Inc. : Announced that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy. Theratechnologies Inc.
shares T.TH are trading up $0.75 at $3.75.
